Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification-Reference-Cited by-同舟云学术

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification

Published:2014-11-04 Issue:2 Volume:112 Page:290-295
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Defferrari R,Mazzocco K,Ambros I M,Ambros P F,Bedwell C,Beiske K,Bénard J,Berbegall A P,Bown N,Combaret V,Couturier J,Erminio G,Gambini C,Garaventa A,Gross N,Haupt R,Kohler J,Jeison M,Lunec J,Marques B,Martinsson T,Noguera R,Parodi S,Schleiermacher G,Tweddle D A,Valent A,Van Roy N,Vicha A,Villamon E,Tonini G P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014557.pdf

Reference26 articles.

1. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF (2011) A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17 (4): 792–804.

2. Ambros PF, Ambros IM SIOP Europe Neuroblastoma Pathology, Biology and Bone Marrow Group (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37 (6): 492–504.

3. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM (2009) International consensus for neuroblastoma molecular diagnostic: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100 (9): 1471–1482.

4. Breslow N, McCann B (1971) Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31 (12): 2098–2103.

5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-MYC in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (4653): 1121–1124.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrence or progression of neuroblastoma in children with MYCN amplification, 1p deletion or 11q deletion may due to altered immune status;2023-07-03

2. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification;Journal of Clinical Oncology;2023-06-10

3. Neuroblastoma;EMC - Pediatría;2023-03

4. Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification;Frontiers in Oncology;2023-02-14

5. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and withoutMYCNAmplification: A Children's Oncology Group (COG) Report;Clinical Cancer Research;2023-02-07